LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Breakthrough T1D, a New York-based global type 1 diabetes (T1D) research and advocacy organisation, to support its thymus programme exploring how to induce immune tolerance to pancreatic islet transplantation.

The research will support pre-clinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation in Type 1 diabetes. The research further builds on Dr. Lagasse's foundational work in thymic biology and immune reprogramming and reinforces the scientific platform underlying LyGenesis's cell therapies.

The award is provided to Dr. Eric Lagasse, professor of Pathology, University of Pittsburgh, and chief scientific officer at LyGenesis.

"We are grateful for the support of our translational research pipeline, which continues to expand beyond liver regeneration," said Dr. Lagasse.

LyGenesis was recently featured in Nature Biotechnology in 'Thymus Renaissance Poised to Boost Health and Longevity', which highlighted the growing scientific understanding of thymic biology and its emerging importance in immune regeneration, cancer response, and longevity. The publication recognised LyGenesis among a select group of biotechnology companies advancing novel approaches to thymus regeneration and immune system restoration.